PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas

Ras proteins, most notably KRas, are prevalent oncogenes in human cancer. Plasma membrane localization and thereby signaling of KRas is regulated by the prenyl‐binding protein PDEδ. Recently, we have reported the specific anti‐proliferative effects of PDEδ inhibition in KRas‐dependent human pancreat...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2019-02, Vol.144 (4), p.767-776
Main Authors: Klein, Christian H., Truxius, Dina C., Vogel, Holger A., Harizanova, Jana, Murarka, Sandip, Martín‐Gago, Pablo, Bastiaens, Philippe I.H.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Apoptosis - drug effects
Apoptosis - genetics
Benzimidazoles - pharmacology
Biotechnology
Cancer
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Proliferation - genetics
Cell survival
Cell Survival - drug effects
Cell Survival - genetics
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - genetics
Colorectal Neoplasms - metabolism
Colorectal Neoplasms - pathology
Cyclic Nucleotide Phosphodiesterases, Type 6 - antagonists & inhibitors
Cyclic Nucleotide Phosphodiesterases, Type 6 - genetics
Cyclic Nucleotide Phosphodiesterases, Type 6 - metabolism
Dependence
Epidermal growth factor receptors
Gene Expression Regulation, Neoplastic - drug effects
HCT116 Cells
HT29 Cells
Humans
Inhibition
K-Ras protein
KRas
Localization
Medical research
Molecular Cancer Biology
Mutation
Pancreas
PDEδ
proliferation
Proteins
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins B-raf - metabolism
Proto-Oncogene Proteins p21(ras) - genetics
Proto-Oncogene Proteins p21(ras) - metabolism
RNA Interference
Tumor cell lines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ras proteins, most notably KRas, are prevalent oncogenes in human cancer. Plasma membrane localization and thereby signaling of KRas is regulated by the prenyl‐binding protein PDEδ. Recently, we have reported the specific anti‐proliferative effects of PDEδ inhibition in KRas‐dependent human pancreatic ductal adenocarcinoma cell lines. Here, we investigated the proliferative dependence on the solubilizing activity of PDEδ of human colorectal cancer (CRC) cell lines with or without oncogenic KRas mutations. Our results show that genetic and pharmacologic interference with PDEδ specifically inhibits proliferation and survival of CRC cell lines harboring oncogenic KRas mutations whereas isogenic cell lines in which the KRas oncogene has been removed, or cell lines with oncogenic BRaf mutations or EGFR overexpression are not dependent on PDEδ. Pharmacological PDEδ inhibition is therefore a possible new avenue to target oncogenic KRas bearing CRC. What's new? Oncogenic KRas mutations are present in about 45% of colorectal cancers (CRCs), where they are associated with poor prognosis. While KRas is an appealing therapeutic target, it has repeatedly eluded small‐molecule inhibitors. Here, the authors chose instead to target PDEδ, a prenyl‐binding protein that regulates the plasma membrane localization of KRas. In experiments in human colorectal cancer cells, PDEδ inhibition limited proliferation and survival in cells harboring KRas mutations, with no effect on wild‐type KRas cells, providing a new therapeutiv opportunity for CRC harbouring oncogenic KRas. In addition, PDEδ protein expression was correlated with oncogenic KRas activity within the CRC cell panel, suggesting that PDEδ protein‐level determination may be of prognostic relevance for CRC patients.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.31859